What are the typical symptoms of angina and the recommended acute and chronic management, including pharmacologic therapy and lifestyle modifications?

Angina Symptoms and Management

For acute angina relief, sublingual nitroglycerin (or spray) should be used immediately, with patients instructed to take up to 3 doses at 5-minute intervals and seek emergency care if pain persists beyond 15-20 minutes or after 3 doses. 1

Typical Symptoms

Angina presents as deep, poorly localized chest or arm discomfort that is:

• Reproducibly triggered by physical exertion or emotional stress
• Relieved promptly (within 5 minutes) by rest and/or sublingual nitroglycerin
• Often described as pressure, tightness, or heaviness rather than sharp pain 2, 3

Critical caveat: Many patients—particularly women and elderly—present with atypical symptoms including:

• Isolated dyspnea on exertion (most common anginal equivalent)
• Jaw, neck, ear, shoulder, back, or epigastric discomfort
• Nausea, vomiting, diaphoresis, or unexplained fatigue
• No chest discomfort whatsoever 2, 3

Only 10-25% of patients present with classic anginal symptoms; 57-78% have less characteristic presentations 4.

Acute Management

Immediate Relief Protocol

1. Stop activity immediately when angina occurs
2. Sublingual nitroglycerin: First dose immediately
3. If no relief in 5 minutes: Second dose
4. If no relief in another 5 minutes: Third dose
5. Call 9-1-1 if pain persists >15-20 minutes or after 3 doses 1

Hospital Management (for unstable angina/NSTEMI)

• Bed rest with continuous ECG monitoring 1
• Intravenous nitroglycerin for ongoing ischemia 1
• Supplemental oxygen if SaO2 <90% 1
• Morphine sulfate IV if symptoms persist despite nitroglycerin or if pulmonary congestion present 1

Chronic Management: Pharmacologic Therapy

Disease-Modifying Agents (Prevent MI and Death)

All patients with chronic stable angina must receive 5:

1. Aspirin 75-325 mg daily (Level A evidence)

   • If contraindicated: Clopidogrel 75 mg daily (Level B evidence)

2. Beta-blocker (Level A in post-MI; Level B without MI)

   • Preferred first-line for both symptom relief AND mortality reduction
   • Particularly critical in patients with prior MI 5

3. Statin therapy targeting LDL-cholesterol (Level A evidence)

   • Goal: LDL <100 mg/dL (some guidelines suggest <125 mg/dL) 1

4. ACE inhibitor (Level A evidence)

   • Mandatory in patients with diabetes, LV dysfunction (EF <40%), hypertension, or heart failure
   • Strong evidence supports use in all CAD patients regardless of these conditions 5

Antianginal Therapy Algorithm

Step 1: Beta-blocker as first-line 6

• Preferred because it both relieves angina AND reduces hospitalization/death risk
• Use selective beta-1 antagonists (bisoprolol, metoprolol succinate, or nebivolol) 6

If beta-blocker contraindicated or not tolerated, alternatives include 6, 5:

• Ivabradine (if in sinus rhythm) - Level A evidence
• Long-acting calcium channel blockers (amlodipine, diltiazem, or verapamil) - Level A evidence
  • Critical warning: Avoid short-acting dihydropyridines (increase adverse events) 5
  • Avoid nondihydropyridines (diltiazem/verapamil) if LV dysfunction present 7, 1
• Long-acting nitrates - Level A evidence
• Nicorandil - Level C evidence (safety in HF uncertain)
• Ranolazine - Level C evidence (safety in HF uncertain)

Step 2: Add second antianginal if symptoms persist 6:

• Add ivabradine (Level A)
• Add long-acting nitrate (Level A)
• Add amlodipine (Level A)
• May consider adding nicorandil or ranolazine (Level C)

Combination to avoid: Beta-blocker plus nondihydropyridine CCB (diltiazem/verapamil) increases risk of bradyarrhythmias and heart failure 7

Agents NOT Recommended

• Dipyridamole (Level B evidence against use) 5
• Chelation therapy (Level B evidence against use) 5

Lifestyle Modifications

Essential interventions for all patients:

• Smoking cessation (absolute priority)
• Mediterranean diet adherence 8
• Weight management targeting normal BMI
• Structured exercise program - ideally within cardiac rehabilitation setting 1, 8
  • Enhances functional capacity and reduces adverse events
  • Improves quality of life significantly

Special Considerations

Target Blood Pressure

• <130/80 mm Hg in patients with CAD
• Consider <120/80 mm Hg if ventricular dysfunction present
• Caution: Avoid lowering diastolic BP below 60 mm Hg (may worsen myocardial ischemia) 7

Post-Discharge Instructions

Patients must understand:

• Pattern change warning: More frequent, severe, or rest angina requires immediate physician contact 1
• Proper sublingual nitroglycerin use and storage
• All discharge medications with clear purpose and side effects 1
• Enrollment in cardiac rehabilitation program strongly recommended 1

INOCA (Ischemia with Non-Obstructive Coronary Arteries)

If symptoms persist after ruling out obstructive CAD, consider:

• Microvascular angina: Treat with beta-blockers (carvedilol first-line), consider ACE inhibitors and statins 9
• Vasospastic angina: Calcium channel blockers (verapamil) first-line, add long-acting nitrates second-line 9
• Requires invasive coronary function testing for precise endotype diagnosis 9

Common pitfall: Assuming absence of obstructive CAD means no cardiac cause—functional coronary disorders (microvascular dysfunction, vasospasm) require specific targeted therapy 4, 9.